131I-MIBG Alone VS. 131I-MIBG With Vincristine and Irinotecan VS131I-MIBG With Vorinostat

Inclusion Criteria:

   - Patients must be > 24 months and < 30 years of age when registered on study.

   - Patients must have relapsed neuroblastoma, refractory neuroblastoma that had less than
   a partial response to standard treatment or persistent neuroblastoma that had at least
   a partial response to frontline therapy frontline therapy with > 3 residual lesions on
   end-induction MIBG scan.

   - Patients must have evidence of MIBG uptake into tumor at ≥ one site within 4 weeks
   prior to entry on study and subsequent to any intervening therapy.

   - Patients must have adequate heart, kidney, liver and bone marrow function. Patients
   who have bone marrow disease must still have adequate bone marrow function to enter
   the study.

   - Patients must have a dose of unpurged peripheral blood stem cells is 2.0 x 106 viable
   CD34+ cells/kg available.

Exclusion Criteria:

   - They have had previous I-131 MIBG therapy

   - They have other medical problems that could get much worse with this treatment.

   - They are pregnant or breast feeding.

   - They have a history of a venous or arterial thrombosis that was not associated to a
   central line.

   - They have active infections such as hepatitis or fungal infections.

   - They have active diarrhea.

   - They have had an allogeneic stem cell transplant (received stem cell from someone
   else)

   - They can't cooperate with the special precautions that are needed for this trial.